I'm wondering ...
I'm wondering ... if the future of Trogarzo is as rosy as we all here believe (and believe for many good reasons), then why doesn't a big pharma swallow THERF at this ridiculously low market cap. As good of research as many here provide, big pharma would know sooooo much more of Trogarzo's potential and pay handsomely if they knew it was a slam-dunk. Again ... just wondering (still long & strong)! -LT